← Back to Search
Inhibition Of The Met Receptor In Mesothelioma
T. Mukohara, Gabriel Civiello, I. Davis, M. Taffaro, J. Christensen, D. Fisher, B. Johnson, P. Jänne
Published 2005 · Medicine, Biology
Download PDFAnalyze on Scholarcy
Background: Expression of the Met receptor and its ligand, hepatocyte growth factor (HGF), has been observed in 74% to 100% and 40% to 85% of malignant pleural mesothelioma (MPM) specimens, respectively. HGF stimulation has been shown to enhance MPM cell proliferation, migration, cell scattering, and invasiveness. Experimental Design: To investigate a potential therapeutic role for the Met receptor in MPM, we examined the effects of PHA-665752, a specific small-molecule inhibitor of the Met receptor tyrosine kinase, in a panel of 10 MPM cell lines. Results: Two of the cell lines, H2461 and JMN-1B, exhibited autocrine HGF production as measured by ELISA (3.9 and 10.5 ng/mL, respectively, versus <0.05 ng/mL in other cell lines). Evaluation of PHA-665752 across the 10 MPM cell lines indicated that despite Met expression in all cell lines, only in cell lines that exhibited a Met/HGF autocrine loop, H2461 and JMN-1B, did PHA-665752 inhibit growth with an IC50 of 1 and 2 μmol/L, respectively. No activating mutations in Met were detected in any of the cell lines. Consistent with observed growth inhibition, PHA-665752 caused cell cycle arrest at G1-S boundary accompanied by a dose-dependent decrease in phosphorylation of Met, p70S6K, Akt, and extracellular signal-regulated kinase 1/2. Growth of H2461 cells was also inhibited by neutralizing antibodies to HGF and by RNA interference knockdown of the Met receptor, confirming that growth inhibition observed was through a Met-dependent mechanism. PHA-665752 also reduced MPM in vitro cell migration and invasion. Conclusions: Taken together, these findings suggest that inhibition of the Met receptor may be an effective therapeutic strategy for patients with MPM and provides a mechanism, the presence of a HGF/Met autocrine loop, by which to select patients for PHA-665752 treatment.
This paper references
Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells
Michal Firon (2000)
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma.
G. Gordon (2002)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
G. Maulik (2002)
Somatic mutations of the METoncogene are selected during metastatic spread of humanHNSC carcinomas
MF DiRenzo (2000)
Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines.
G. Shapiro (1999)
Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance.
J. Klominek (1993)
Role of focal adhesion proteins in signal transduction and oncogenesis.
E. Weisberg (1997)
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering
S. Tanimura (1998)
Hepatocyte growth factor/scatter factor is present in most pleural effusion fluids from cancer patients.
G. Eagles (1996)
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
Sylvie Berthou (2004)
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma
E. Tolnay (1998)
Hepatocyte Growth Factor Induces ERK-dependent Paxillin Phosphorylation and Regulates Paxillin-Focal Adhesion Kinase Association*
Zhenxiang Liu (2002)
Immunoreactivity for cadherins, HGF/SF, met, and erbB‐2 in pleural malignant mesotheliomas
I. Thirkettle (2000)
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.
G. Demetri (1989)
Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor*
S. Ried (1999)
SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma
P. Cacciotti (2001)
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas.
W. Park (1999)
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Laura Schmidt (1999)
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
J. Christensen (2003)
Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion.
G. Davies (2001)
Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology.
P. Harvey (1998)
Gefitinib in patients with malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30101)
R Govindan (2003)
Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.
G. Bepler (1988)
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
P. Jänne (2002)
Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis.
Shuta Ishibe (2004)
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors.
Alla Danilkovitch-Miagkova (2002)
Characteristics of nine newly derived mesothelioma cell lines.
H. Pass (1995)
Therapeutic Targeting of Multiple Signaling Pathways in Malignant Pleural Mesothelioma
T. Mukohara (2005)
Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
P. Peschard (2001)
Advances in Brief Gefitinib Induces Apoptosis in the EGFRL 858 R Non – Small-Cell Lung Cancer Cell Line H 3255
S. Tracy (2004)
c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
P. Ma (2003)
Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma.
Maria E. Ramos-Nino (2003)
A Conserved DpYR Motif in the Juxtamembrane Domain of the Met Receptor Family Forms an Atypical c-Cbl/Cbl-b Tyrosine Kinase Binding Domain Binding Site Required for Suppression of Oncogenic Activation*
P. Peschard (2004)
in papillary renal carcinomas
S Berthou (1999)
Alteration of Met protooncogene product expression and prognosis in breast carcinomas.
I. Tsarfaty (1999)
Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases
P. Harvey (2000)
Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
S. Tracy (2004)
Func - tional expression and mutations of c - Met and its therapeutic inhibition with SU 11274 and small interfering RNA in non - small cell lung cancer
JagadeeswaranR MaPC (2005)
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
L. Strizzi (2001)
The mutationally activated Met receptor mediates motility and metastasis.
M. Jeffers (1998)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
L. Schmidt (1997)
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
M. D. Renzo (2000)
IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS
P. Harvey (1996)
Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelioma cells through c‐met receptor
J. Klominek (1998)
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer.
M. Tsao (2001)
A novel germ line juxtamembrane Met mutation in human gastric cancer
J. Lee (2000)
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
P. Ma (2005)
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
D. Bottaro (1991)
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.
C. Qian (2002)
Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody.
H. Dazzi (1990)
Ther - apeutic targetingofmultiple signalingpathways inma - lignant pleural mesothelioma
Phase III study of pemetrexed in combinationwith cisplatin versus cisplatin alone in patients with malignant pleuralmesothelioma
NJ Vogelzang (2003)
An epithelial scatter factor released by embryo fibroblasts.
M. Stoker (1985)
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
G. Maulik (2002)
Hepatocyte growth factor / scatter factor and its receptor c - Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelio
E Tolnay (1998)
Chemotherapy formalignant pleuralmesothelioma
PA Janne (2003)
Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM).
L. Garland (2004)
[Malignant pleural mesothelioma].
Q. Kong (1983)
This paper is referenced by
MET as a target for treatment of chest tumors.
N. Cipriani (2009)
c-MET Immunohistochemistry For Differentiating Malignant Mesothelioma from Benign Mesothelial Proliferations.
Hezhen Ren (2020)
Inhibition of c-Met as a Therapeutic Strategy for Esophageal Adenocarcinoma
G. Watson (2006)
Advances in the systemic therapy of malignant pleural mesothelioma
D. Fennell (2008)
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
T. Mukohara (2009)
c-Met Axis − miR-34 a − Mesotheliomas with Enriched Cancer Stem Cells via a p 53 Tumor Suppressor Alterations Cooperate to Drive Aggressive
Craig W. Menges (2014)
Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma
G. Pinton (2012)
Advances in malignant pleural mesothelioma therapy: targeting EphA2 a novel approach.
N. Nasreen (2012)
Malignant pleural mesothelioma cells resist anoikis as quiescent pluricellular aggregates
J. Daubriac (2009)
Malignant pleural mesothelioma: current and future perspectives.
Konstantinos Porpodis (2013)
Current World Literature
Pleural mesothelial cells in pleural and lung diseases.
H. Batra (2015)
Single-Agent and Combination Therapeutic Strategies to Inhibit Hepatocyte Growth Factor/MET Signaling in Cancer
L. Toschi (2008)
Human papillomavirus type 16 E 6 suppresses microRNA-23 b expression in human cervical cancer cells through DNA methylation of the host gene C 9 orf 3
C. A. Yeung (2017)
HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.
Maria E. Ramos-Nino (2008)
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line
Y. Funakoshi (2013)
DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma
H. Wang (2017)
Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma
Chandrani Chattopadhyay (2008)
HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis
G. Gaudino (2014)
Genetics and molecular biology of mesothelioma.
D. Fennell (2011)
Single-Agent and CombinationTherapeutic Strategies to Inhibit Hepatocyte Growth Factor / MET Signaling in Cancer
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
K. Kawaguchi (2009)
Anticancer Drug Response Prediction in Cell Lines Using Weighted Graph Regularized Matrix Factorization
Na-Na Guan (2019)
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
W. Ou (2011)
AXL regulates mesothelioma proliferation and invasiveness
W. Ou (2011)
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou (2014)
Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.
C. Menges (2014)
Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.
Bao-Zhu Yuan (2008)
Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma.
S. Uddin (2011)
The role of the HGF/Met axis in mesothelioma.
Thivyan Thayaparan (2016)
Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys
T. Kakkar (2007)
Inhibition of ligand‐independent constitutive activation of the Met oncogenic receptor by the engineered chemically‐modified antibody DN30
E. Vigna (2015)See more